Sethuraman Natarajan
SEC CIK 1873394 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| TRDA | Entrada Therapeutics, Inc. | Pres, Research, Develop | 214.2K | — | $1.90M | 26 | 2022-03-01 | 2026-09-02 |
Most active insiders at TRDA, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | PARMAR KUSH | Dir, 10% | — | $3.65M |
| 2 | MPM BIOVENTURES 2018, L.P. | 10% | — | $3.60M |
| 3 | MPM BioVentures 2014, L.P. | 10% | — | $3.60M |
| 4 | 5AM Ventures V, L.P. | 10% | — | $3.00M |
| 5 | Baker Bros. Advisors (GP) LLC | 10% | $1.35M | — |
| 6 | WENTWORTH KORY JAMES | CFO | — | $433.6K |
| 7 | Dowden Nathan J | Pres, COO | — | $425.7K |
| 8 | Sethuraman Natarajan | Pres, Research, Develop | — | $398.8K |
| 9 | BAKER FELIX | 10% | $261.8K | — |
| 10 | Zeiher Bernhardt G | Dir | $29.3K | — |
Transactions 26
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-03 17:16 | 2026-09-02 | TRDA | Entrada Therapeutics, Inc. | Sethuraman Natarajan | Pres, Research, Develop | F - Tax | $7.14 | -2,079 | 214.2K | -1.0% | -$14.9K | |
| T | 2026-05-04 19:25 | 2026-05-04 | TRDA | Entrada Therapeutics, Inc. | Sethuraman Natarajan | Pres, Research, Develop | S - Sale | $15.39 | -25.9K | 216.3K | -11% | -$398.8K |
| D | 2026-03-03 | 2026-03-01 | TRDA | Entrada Therapeutics, Inc. | Sethuraman Natarajan | Pres, Research, Develop | A - Grant | $0.00 | +55.8K | 253.7K | +28% | $0 |
| DM | 2026-03-03 | 2026-03-02+ | TRDA | Entrada Therapeutics, Inc. | Sethuraman Natarajan | Pres, Research, Develop | F - Tax | $11.73 | -11.5K | 242.2K | -5% | -$134.6K |
| 2025-09-04 | 2025-09-02 | TRDA | Entrada Therapeutics, Inc. | Sethuraman Natarajan | Pres, Research, Develop | F - Tax | $5.43 | -1,760 | 197.9K | -0.9% | -$9,557 | |
| D | 2025-03-04 | 2025-03-03 | TRDA | Entrada Therapeutics, Inc. | Sethuraman Natarajan | Pres, Research, Develop | F - Tax | $11.68 | -6,138 | 199.7K | -3% | -$71.7K |
| D | 2025-03-04 | 2025-03-01 | TRDA | Entrada Therapeutics, Inc. | Sethuraman Natarajan | Pres, Research, Develop | A - Grant | $0.00 | +60.8K | 205.8K | +42% | $0 |
| M | 2024-12-03 | 2024-11-29+ | TRDA | Entrada Therapeutics, Inc. | Sethuraman Natarajan | Pres, Research, Develop | S - Sale | $20.18 | -15.9K | 156.7K | -9% | -$320.6K |
| M | 2024-11-13 | 2024-11-11+ | TRDA | Entrada Therapeutics, Inc. | Sethuraman Natarajan | Pres, Research, Develop | S - Sale | $20.03 | -4,109 | 160.9K | -2% | -$82.3K |
| M | 2024-11-06 | 2024-11-04+ | TRDA | Entrada Therapeutics, Inc. | Sethuraman Natarajan | Pres, Research, Develop | S - Sale | $18.62 | -18.2K | 177.3K | -9% | -$339.3K |
| 2024-10-18 | 2024-10-16 | TRDA | Entrada Therapeutics, Inc. | Sethuraman Natarajan | Pres, Research, Develop | S - Sale | $18.00 | -600 | 183.2K | -0.3% | -$10.8K | |
| M | 2024-09-10 | 2024-09-06+ | TRDA | Entrada Therapeutics, Inc. | Sethuraman Natarajan | CSO | S - Sale | $15.12 | -3,242 | 186.5K | -2% | -$49.0K |
| M | 2024-09-05 | 2024-09-03+ | TRDA | Entrada Therapeutics, Inc. | Sethuraman Natarajan | CSO | F - Tax | $15.63 | -1,756 | 188.2K | -0.9% | -$27.4K |
| M | 2024-07-16 | 2024-07-12+ | TRDA | Entrada Therapeutics, Inc. | Sethuraman Natarajan | CSO | S - Sale | $18.00 | -1,238 | 188.8K | -0.7% | -$22.3K |
| M | 2024-05-20 | 2024-05-16+ | TRDA | Entrada Therapeutics, Inc. | Sethuraman Natarajan | CSO | S - Sale | $15.16 | -19.0K | 190.1K | -9% | -$287.7K |
| D | 2024-03-05 | 2024-03-01 | TRDA | Entrada Therapeutics, Inc. | Sethuraman Natarajan | CSO | A - Grant | $0.00 | +44.1K | 211.3K | +26% | $0 |
| DM | 2024-03-05 | 2024-03-04+ | TRDA | Entrada Therapeutics, Inc. | Sethuraman Natarajan | CSO | F - Tax | $12.50 | -2,266 | 209.0K | -1% | -$28.3K |
| D | 2023-09-06 | 2023-09-05 | TRDA | Entrada Therapeutics, Inc. | Sethuraman Natarajan | CSO | F - Tax | $14.46 | -449 | 167.2K | -0.3% | -$6,493 |
| D | 2023-09-06 | 2023-09-01 | TRDA | Entrada Therapeutics, Inc. | Sethuraman Natarajan | CSO | A - Grant | $0.00 | +14.2K | 167.6K | +9% | $0 |
| M | 2023-07-12 | 2023-07-10+ | TRDA | Entrada Therapeutics, Inc. | Sethuraman Natarajan | CSO | S - Sale | $18.03 | -17.9K | 153.4K | -10% | -$322.4K |
| DA | 2023-04-19 | 2023-03-01 | TRDA | Entrada Therapeutics, Inc. | Sethuraman Natarajan | CSO | A - Grant | $0.00 | +14.2K | 175.3K | +9% | $0 |
| 2023-04-19 | 2023-04-17 | TRDA | Entrada Therapeutics, Inc. | Sethuraman Natarajan | CSO | S - Sale | $18.00 | -3,961 | 171.3K | -2% | -$71.3K | |
| D | 2023-03-03 | 2023-03-01 | TRDA | Entrada Therapeutics, Inc. | Sethuraman Natarajan | CSO | A - Grant | $0.00 | +28.4K | 190.5K | +18% | $0 |
| D | 2023-03-03 | 2023-03-02 | TRDA | Entrada Therapeutics, Inc. | Sethuraman Natarajan | CSO | F - Tax | $11.60 | -1,058 | 189.5K | -0.6% | -$12.3K |
| 2022-09-06 | 2022-09-01 | TRDA | Entrada Therapeutics, Inc. | Sethuraman Natarajan | CSO | A - Grant | $0.00 | +5,794 | 162.1K | +4% | $0 | |
| D | 2022-03-03 | 2022-03-01 | TRDA | Entrada Therapeutics, Inc. | Sethuraman Natarajan | CSO | A - Grant | $0.00 | +11.6K | 156.3K | +8% | $0 |
Purchase Sale Sale after option exercise All abbreviations